中图分类号 R956；R979.1 文献标志码 A 文章编号 1001-0408(2025)11-164-06

    DOI 10.609/j.issn.1001-0408.2025.11.1

    ABSTRACT OBJECTIVE To estimate the cost-effectiveness of penpulimab combined with chemotherapy versus chemotherapy alone in first-line treatment of advanced squamous non-small-cell lung cancer(sq-NSCLC). METHODS From the perspective of Chinese health system，cost-utility analysis was used to evaluate the cost-effectiveness of penpulimab combined with chemotherapy (paclitaxel + carboplatin)versus chemotherapy(paclitaxel + carboplatin)in first-line treatment of sq-NSCLC. A three-health states Markov model was constructed with R packages，and clinical data used in the model were derived from the AK105-302 clinical trial. Costs and utilities were collected from the open-access database and published literature. The quality-adjusted life-years (QALY)was used as the utility index，and the willingness-to-pay(WTP)threshold was set at three times China’s per capita GDP in 2024，equivalent to 287 247 yuan/QALY. The cost-effectiveness of the schemes was evaluated by comparing the incremental costutility ratios(ICER)of the two schemes with the WTP threshold. One-way sensitivity analysis and probabilistic sensitivity analysis(PSA) were used to verify the stability of the basic analysis results. RESULTS Compared with chemotherapy ......